Results 181 to 190 of about 1,845,771 (290)

A Novel Reactive Oxygen Species‐Responsive Bone‐Targeted Nanoplatform Based on Cloperastine Attenuates Ovariectomy‐Induced Bone Loss by Inhibiting Osteoclast Oxidative Phosphorylation

open access: yesAdvanced Science, EarlyView.
Cloperastine suppresses osteoclastogenesis by inhibiting PGC1β‐mediated oxidative phosphorylation. Its incorporation into a ROS‐responsive, Asp8‐modified nanoplatform enhances skeletal accumulation. The resulting Clo/Asp8‐PMK‐MCs combine cloperastine‐mediated antiresorptive activity with carrier‐mediated osteogenic activity to attenuate OVX‐induced ...
Haibo Liang   +16 more
wiley   +1 more source

Meningeal Lymphatic LTBR Deficiency Links Spinal Cord Injury to Secondary Brain Pathology

open access: yesAdvanced Science, EarlyView.
Spinal cord injury (SCI) induces remote brain alterations beyond the injured spinal cord. This study links dysfunction of meningeal lymphatic vessels (mLVs) to neuroinflammation and neuronal injury after SCI. LTBR‐mediated lymphatic restoration improves meningeal lymphatic integrity and neurological outcomes, highlighting LTBR as a potential regulator ...
Yi Chen   +12 more
wiley   +1 more source

A Biomimetic cRGDyk‐Engineered Platelet Nanoplatform for ACAD11 Delivery to Trigger Pyroptosis in Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
A biomimetic platelet nanoplatform (OE‐ACAD11@R‐PLT) is developed for targeted hepatocellular carcinoma immunotherapy. By selectively delivering therapeutic plasmids, this system induces mitochondrial dysfunction and triggers robust NLRP3/Caspase‐1/GSDMD‐mediated pyroptosis in tumor cells.
Hongyi Bao   +12 more
wiley   +1 more source

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

open access: yesAdvanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy